Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Канада - англійська - Health Canada

pharmascience inc - estradiol - tablet - 0.5mg - estradiol 0.5mg - estrogens

Канада - англійська - Health Canada

pharmascience inc - estradiol - tablet - 1mg - estradiol 1mg - estrogens

Канада - англійська - Health Canada

pharmascience inc - estradiol - tablet - 2mg - estradiol 2mg - estrogens

США - англійська - NLM (National Library of Medicine)

pharmacia & upjohn company llc - estradiol cypionate (unii: 7e1dv054lo) (estradiol - unii:4ti98z838e) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: estrogens should not be used in individuals with any of the following conditions: there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobutanol anhydrous (chloral derivative) added as a preservative may be habit forming.

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - estradiol cypionate (unii: 7e1dv054lo) (estradiol cypionate - unii:7e1dv054lo) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: - moderate to severe vasomotor symptoms associated with the menopause. - hypoestrogenism due to hypogonadism. estrogens should not be used in individuals with any of the following conditions: - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - depo-estradiol should not be used in patients with known hypersensitivity to its ingredients. - known or suspected pregnancy. there is no indication for depo-estradiol in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobu

США - англійська - NLM (National Library of Medicine)

noven therapeutics, llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 0.05 mg in 1 d - combipatch is indicated in a woman with a uterus for: - treatment of moderate to severe vasomotor symptoms due to menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. combipatch is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen-dependent neoplasia. - active dvt, pe, or history of these conditions. - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema or hypersensitivity with combipatch. - known liver impairment or disease. - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders. - known or suspected pregnancy. combipatch (käm-bē `pach) (estradiol/norethindrone acetate transdermal system) step 1. pick the days you will change your combipatch. - you will need to change your patch every 3 to 4 days (twice weekly). step 2. remove combipatch from the pouch. - tear open the protective pouch at the slit (do not use scissors) and remove the patch. see figure a. - the pouch should not be opened until you are ready to put the patch on. step 3. remove the adhesive liner. - peel off one side of the protective liner. see figure b. - do not touch the sticky part of the patch with your fingers. see figure b. step 4. placing the combipatch on your skin. - put the sticky side of the patch on the lower abdomen (below the panty line). see figure c. - peel off the second side of the protective liner. see figure c. - press the patch firmly in place with your hand for about 10 seconds. see figure d. note: - avoid the waistline, since clothing and belts may cause the combipatch to be rubbed off. - do not apply the combipatch to or near your breasts. - only apply the combipatch to skin that is clean, dry, and free of any powder, oil, or lotion. - you should not apply the combipatch to injured, burned, or irritated skin, or areas with skin conditions (such as birth marks, tattoos, or that is very hairy). step 5. press the combipatch firmly onto your skin. - rub the edges of the combipatch with your fingers to make sure that it will stick to your skin. see figure e. note: - bathing, swimming, or showering will not affect the combipatch. - once in place, the patch should not be exposed to the sun for prolonged periods of time. - if your combipatch falls off reapply it. if you cannot reapply the combipatch, apply a new combipatch to another area (see figures c , d and e) and continue to follow your original placement schedule. - if you stop using your combipatch or forget to apply a new combipatch as scheduled you may have spotting, or bleeding, and your symptoms may come back. step 6. throwing away your used combipatch. - when it is time to change your combipatch, remove the old combipatch before you apply a new one. - to throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash. used patches should not be flushed in the toilet. this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured by: noven pharmaceuticals inc. miami, fl 33186 distributed by: noven therapeutics, llc miami, fl 33186 for more information call 1-800-455-8070 or visit www.combipatch.com. © 2024 noven pharmaceuticals, inc. 102538-5 02/2024

США - англійська - NLM (National Library of Medicine)

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d

США - англійська - NLM (National Library of Medicine)

par pharmaceutical - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.25 mg - previfem® (norgestimate/ethinyl estradiol tablets) and tri-previfem® (norgestimate/ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . tri-previfem® (norgestimate/ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. previfem® (norgestimate/ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . do not prescribe previfem® or tri-previfem® to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [s